Brainstorm to present biomarker insights supporting nurown's mechanism of action and clinical impact at the 2025 als drug development summit

Presentation of biomarker findings from cerebrospinal fluid analyses workshop on adaptive and decentralized als trial design panel on clinical trial access and the role of patient and caregiver engagement new york , may 6, 2025 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th annual als drug development summit, to take place may 12-14, 2025, in boston, ma. the company's senior leadership team will participate in sessions that highlight insights and expertise gained throughout the nurown® development program, contributing to the broader conversation on the future of als clinical research.
BCLI Ratings Summary
BCLI Quant Ranking